Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo

NCT03371758 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2018-01-23

No results posted yet for this study

Summary

The exact mechanism of impairment of autophagy in vitiligo has not yet been determined.

Conditions

  • Autophagy

Interventions

OTHER

skin biopsy

Punch skin biopsy will be taken from the lesional and non-lesional skin of vitiligo patients as well as healthy skin of controls.

Sponsors & Collaborators

  • Cairo University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2018-05-31
Completion
2018-05-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03371758 on ClinicalTrials.gov